MWNA
INO icon

Marshall Wace North America’s Inovio Pharmaceuticals INO Stock Holding History

Marshall Wace North America’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14,487
Closed -$1.61M – 1601
2021
Q1 		$1.61M Buy
+14,487
New +$1.91M 0.01% 891

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace North America's INO Position: Q2 2021 in Review

Marshall Wace North America sold out of Inovio Pharmaceuticals (INO) in Q2 2021, closing a stake of 14,487 shares — an estimated $1.61M sold.

Marshall Wace North America first reported a position in INO in Q1 2021 and held it in 1 quarter. The position peaked at $1.61M in Q1 2021. 211 funds tracked by Wall St. Rank hold INO as of Q2 2021.

  • Marshall Wace North America reported no remaining Inovio Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 14,487 Inovio Pharmaceuticals shares in Q2 2021, an estimated $1.61M.
  • Marshall Wace North America first reported a position in Inovio Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Inovio Pharmaceuticals position peaked at $1.61M in Q1 2021.
  • 211 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.